Missoula, Montana, USA, November 6, 2026
Inimmune Corporation, a clinical-stage biotechnology company developing innovative immunotherapies and immune-modulating technologies, has announced encouraging Phase 1 clinical trial findings for INI-4001, an investigational small-molecule Toll-like receptor 7/8 (TLR7/8) agonist being developed as a potential cancer immunotherapy. The findings were presented as a late-breaking poster at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. The study evaluated INI-4001 in heavily pretreated patients with advanced solid tumors and demonstrated evidence of immune pathway activation, alongside a safety and tolerability profile that supports further clinical investigation. According to the company, the study reported no dose-limiting toxicities (DLTs) and dose-responsive cytokine production, indicating that the investigational treatment activated its intended immune targets. These findings provide important early clinical evidence supporting the continued development of INI-4001 for patients with advanced cancers who may have limited treatment options.
Phase 1 Study Demonstrates TLR7/8 Immune Activation
The Phase 1 clinical study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of INI-4001 in 10 heavily pretreated patients with advanced solid tumors. The investigational treatment was administered intravenously once weekly across five escalating dose levels. The study demonstrated that INI-4001 was tolerated at doses of up to 7.2 micrograms per kilogram, with no dose-limiting toxicities reported. The observed adverse events were primarily transient and consistent with innate immune activation, generally resolving within 24 hours. In addition, the company reported no concerning pharmacokinetic findings. Pharmacodynamic analyses showed dose-responsive cytokine production consistent with the intended activation of the TLR7/8 pathway. At the proposed Phase 2 dose, the maximum increases from pre-dose levels included a 13.5-fold increase in interferon gamma (IFNγ) and a 4.15-fold increase in IP-10. These biomarkers provide evidence of biological activity and support the intended mechanism of action of INI-4001. Researchers also observed temporary, dose-dependent reductions in circulating lymphocytes, with levels returning within 24 hours. This pattern may be consistent with lymphocyte movement from the bloodstream into tissues and tumors, although further research will be required to understand its clinical significance.
Early Patient Observations Support Further Research
Although the Phase 1 study was primarily designed to assess safety and biological activity rather than establish clinical efficacy, the company highlighted observations from two patients who continued receiving INI-4001 through compassionate use. Neither patient had reported disease progression at the time of the announcement. One patient with a small bowel neuroendocrine tumor had received treatment for 19 months, while another patient with chondrosarcoma had received treatment for nine months. These individual observations are preliminary and should not be interpreted as proof of antitumor efficacy. Nevertheless, they provide additional clinical experience that may help inform future investigations. The findings are particularly relevant because INI-4001 is being developed to stimulate innate immune responses, potentially creating conditions that make tumors more responsive to immunotherapy. The company is also interested in exploring whether the treatment could provide additional benefits when administered alongside other cancer therapies.
Advertisement
Inimmune Plans Potential Phase 2a Development in 2027
Based on the Phase 1 findings, Inimmune is evaluating plans to advance INI-4001 into a Phase 2a clinical study as early as 2027, subject to securing the necessary funding or partnership support. The next stage of clinical development is expected to provide further information about the treatment’s safety, biological activity and potential therapeutic value in patients with advanced solid tumors. Future research may also investigate INI-4001 as a monotherapy and in combination with existing cancer treatments. The late-breaking clinical abstract was published in the Journal for ImmunoTherapy of Cancer and presented at the SITC 2026 Annual Meeting by Shannon Miller, Ph.D., Vice President at Inimmune. The company’s broader research focuses on developing immunotherapies, vaccine adjuvants and immune-modulating technologies for cancer, allergy, infectious diseases and autoimmune conditions. Overall, the Phase 1 results represent an important development milestone for Inimmune, demonstrating that INI-4001 can produce measurable immune activation without reported dose-limiting toxicities in the small study population. Further clinical studies will be essential to determine whether this immune activity can translate into meaningful clinical benefits for patients with advanced solid tumors.
Source: Inimmune press release
